Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

24.23 -0.44 (-1.78%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	437,398
Open	24.63
Bid (Size)	24.25 (100)
Ask (Size)	24.27 (100)
Prev. Close	24.67
Today's Range	24.00 - 24.80
52wk Range	22.04 - 53.65
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 ↗

September 11, 2026

The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.

Via The Motley Fool

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 09, 2026

Via Chartmill

Performance

YTD	-39.1%	-39.1%
1 Month	-13.3%	-13.3%
3 Month	-0.2%	-0.2%
6 Month	-52.7%	-52.7%
1 Year	+4.2%	+4.2%

More News

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

September 02, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Announces Appointments to Its Board of Directors

August 13, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 11, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗

June 29, 2026

Via The Motley Fool

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗

June 05, 2026

Via The Motley Fool

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

May 27, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Via The Motley Fool

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 12, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗

May 07, 2026

Via The Motley Fool

Maze Therapeutics Announces $150 Million Registered Offering

April 22, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗

April 04, 2026

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗

March 25, 2026

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 25, 2026

Via Chartmill

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

March 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

March 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗

March 21, 2026

Via The Motley Fool

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

Via The Motley Fool

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗

February 16, 2026

Via The Motley Fool

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?

Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Maze Therapeutics, Inc. - Common Stock trade on?

Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?

The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market

What is the current price of Maze Therapeutics, Inc. - Common Stock?

The current price of Maze Therapeutics, Inc. - Common Stock is 24.23

When was Maze Therapeutics, Inc. - Common Stock last traded?

The last trade of Maze Therapeutics, Inc. - Common Stock was at 09/15/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.